Global COVID-19 Therapeutics Market is expected to grow at a 15.0% CAGR during the forecast period for 2025-2034.
The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics market during the forecast period. According to the World Health Organization (WHO), globally, 175,847,347 confirmed cases of COVID-19, including 3,807,276 deaths, were reported to WHO as of 15 June 2021. Covid-19 cases are increasing day by day, and there is no officially approved drug for COVID-19. Many countries are facing a shortage of drugs likely to offer growth opportunities for pharmaceutical drug manufacturers. Leading market players are also developing innovative and efficient covid-19 drug therapies, resulting in overall market growth.
Major factors responsible for the growth of the COVID 19 therapeutic market are the fast adoption of advanced technologies, the growing number of corona patients, increasing healthcare expenditures, rising awareness about coronavirus, and increasing efforts by the pharmaceutical companies to develop covid-19 therapeutic drugs. For instance, Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 treatments at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Furthermore, increasing research investments for the R&D of covid-19 therapeutic drugs is anticipated to drive market growth in the future. However, the high cost required to validate therapies, and long-term clinical trials limit the COVID-19 therapeutics market growth.
The COVID-19 therapeutics market can be segmented into Drug Class, and Region. By Drug Claas, the market can be divided into Corticosteroids (Dexamethasone, Hydrocortisone, Methylprednisolone, Others (Prednisone, Others)), Anti-viral (Remdesivir, Nirmatrelvir, Others (Ivermectin, Others)), Monoclonal Antibodies (Sotrovimab, Casirivimab plus imdevimab, Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others), Kinase Inhibitors (Baricitinib, Others (Tofacitinib, Others)),Others (anti-inflammatory drugs, convalescent plasma, others). Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the COVID-19 therapeutics market in the coming future.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 15.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025 to 2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AstraZeneca plc, Celltrion Healthcare Co.,Ltd, Pfizer Inc., Ridgeback Biotherapeutics, Merck & Co., Veru Inc., Gilead Sciences, Inc., GSK plc, Shionogi & Company, Limited, NRx Pharmaceuticals, Inc., Kintor Pharma-B, Regeneron Pharmaceuticals, CytoDyn, Atea Pharmaceuticals, Inc., Amarin Corporation, APEIRON Biologics AG, Abivax SA, Alexion Pharmaceuticals, Bellerophon Therapeutics, Blade Therapeutics, Inc, Roivant Sciences, Synairgen, Sorrento Therapeutics, Fulcrum Therapeutics, Ono Pharmaceutical Co., Ltd., Revive Therapeutics Ltd., and other prominent players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global COVID-19 Therapeutics Market Snapshot
Chapter 4. Global COVID-19 Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial Analysis/Pipeline Analysis 2021
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. Corticosteroids
5.2.1.1. Dexamethasone
5.2.1.2. Hydrocortisone
5.2.1.3. Methylprednisolone
5.2.1.4. Others (Prednisone, Others)
5.2.2. Anti-viral
5.2.2.1. Remdesivir
5.2.2.2. Nirmatrelvir
5.2.2.3. Others (Ivermectin, Others)
5.2.3. Monoclonal Antibodies
5.2.3.1. Sotrovimab
5.2.3.2. Casirivimab plus imdevimab
5.2.3.3. Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others)
5.2.4. Kinase Inhibitors
5.2.4.1. Baricitinib
5.2.4.2. Others (Tofacitinib, Others)
5.2.5. Others (anti-inflammatory drugs, convalescent plasma, others)
Chapter 6. COVID-19 Therapeutics Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021-2034
6.1.2. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
6.2. Europe
6.2.1. Europe COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034
6.2.2. Europe COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034
6.3. Asia Pacific
6.3.1. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034
6.3.2. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034
6.4. Latin America
6.4.1. Latin America COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034
6.4.2. Latin America COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034
6.5.2. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. AstraZeneca plc
7.2.2. Celltrion Healthcare Co.,Ltd
7.2.3. Pfizer Inc.
7.2.4. Ridgeback Biotherapeutics
7.2.5. Merck & Co.
7.2.6. Veru Inc.
7.2.7. Gilead Sciences, Inc.
7.2.8. GSK plc
7.2.9. Shionogi & Company, Limited
7.2.10. NRx Pharmaceuticals, Inc.
7.2.11. Kintor Pharma-B
7.2.12. Regeneron Pharmaceuticals
7.2.13. CytoDyn
7.2.14. Atea Pharmaceuticals, Inc.
7.2.15. Amarin Corporation
7.2.16. APEIRON Biologics AG
7.2.17. Abivax SA
7.2.18. Alexion Pharmaceuticals
7.2.19. Bellerophon Therapeutics
7.2.20. Blade Therapeutics, Inc
7.2.21. Roivant Sciences
7.2.22. Synairgen
7.2.23. Sorrento Therapeutics
7.2.24. Fulcrum Therapeutics
7.2.25. Ono Pharmaceutical Co., Ltd.
7.2.26. Revive Therapeutics Ltd.
7.2.27. Eli Lilly and Company
7.2.28. Other Prominent Players
Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 202 to 2030 based on Drug Class
Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
North America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Europe COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Asia Pacific COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Latin America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030
The Middle East & Africa COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Competitive Landscape
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
